Big changes coming. Huge hit to our bottom line. Will our higher ups take a pay cut or will staffs be reduced even more. Scary stuff that we all need to understand.
LCA has HuGE cash , they are diversifying their portfolios and have said so for the pst couple of years. Lab will continue to see significant cuts to drive their CRO and Data businesses.
Stock is at an all time high and barely took a bump back in September when prelim reimbursement numbers were announced. We will make adjustments and it will continue to impact TAT's and service but will not (short term) impact stock price.
Cafepharma is the exact place that will provide insight and improve everyone’s understanding of PAMA... dumbass!
